Skip to main content
Evidence Snapshot

Cannabinoid receptor 1

CHEMBL218 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:08Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL218
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Cannabinoid receptor 1 as ChEMBL target CHEMBL218, mapped to UniProt P21554. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Cannabinoid receptor 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL218
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P21554
Cannabinoid receptor 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Cannabinoid receptor 1 matters

As of 2026-09-13

Cannabinoid receptor 1 is reviewed as Cannabinoid receptor 1 (UniProt P21554); Cannabinoid receptor 1 shows approved-linked disease relevance led by obesity. 5 more disease programs remain visible in the same review block.; 6 linked drugs keep this evidence frame grounded.; the current evidence base includes 21 approved drugs, 12603 compounds, and 1463 assays, with lead potency reaching pChEMBL 11.0.

Disease context
obesity

Cannabinoid receptor 1 shows approved-linked disease relevance led by obesity. 5 more disease programs remain visible in the same review block. 6 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include IBIPINABANT, NABILONE, OTENABANT.

Start review with obesity because it currently carries approved-linked support. Linked drugs include IBIPINABANT, NABILONE, OTENABANT, RIMONABANT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 6 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 21 approved drugs, 12603 compounds, and 1463 assays for this target. The dominant activity type is KI. CHEMBL4062749 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL4062749 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
21 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Cannabinoid receptor 1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P21554, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why obesity is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

12603
Total Compounds
1463
Total Assays
21
Approved Drugs
IC50: 3461.0, KI: 6392.0, EC50: 5010.0, KD: 210.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4062749
 11.0 Ki —
No preferred name
CHEMBL4847866
 10.7 EC50 —
No preferred name
CHEMBL4873473
 10.7 EC50 —
No preferred name
CHEMBL4169198
 10.5 EC50 —
No preferred name
CHEMBL2063237
 10.5 Ki —

Approved Drugs

Structure Compound First Approval
CANNABIDIOL
CHEMBL190461
 2018
RIMONABANT
CHEMBL111
 2006
NABILONE
CHEMBL2218896
 1985
DRONABINOL
CHEMBL465
 1985
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:08Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL218